A Prospective Study of Risedronate on Regional Bone Metabolism and Blood Flow at the Lumbar Spine Measured by18F-Fluoride Positron Emission Tomography

Abstract

The effect of risedronate on bone metabolism at the lumbar spine was assessed in 18 women who had a 18 F-fluoride PET scan at baseline and after 6 months of therapy. The net plasma clearance of fluoride to bone mineral reflecting osteoblastic activity decreased significantly after therapy.

Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography

“…(24,25) In contrast to the findings presented here for teriparatide, Frost et al reported an 18% decrease in K i values at the lumbar spine in 18 postmenopausal women treated with risedronate for 6 months. (21) As in the present study, bone blood flow was unchanged, and the decrease in K i was explained by an 18% decrease in k 3 /(k 2 þ k 3 ). In the only other study we are aware of that used 18 F À PET to examine the regional effects of an osteoporosis therapy, Uchida et al reported a 14% decrease in SUVs at the spine and a 24% decrease at the femoral neck in 24 postmenopausal women treated with alendronate for 12 months for glucocorticoid-induced osteoporosis.…”

“…Radionuclide imaging provides a novel method of studying regional bone metabolism. (17) One of the most widely used techniques is 18 F-fluoride positron emission tomography ( 18 F À PET) analyzed using the method described by Hawkins et al (18)(19)(20)(21)(22)(23) In the Hawkins method, the bone time-activity curve ORIGINAL ARTICLE J JBMR and the arterial tracer input function are analyzed using a threecompartment model to derive the regional bone plasma clearance (K i : units mL min À1 mL À1 ).…”

“…An example is the gamma camera method of measuring the skeletal uptake of 99m Tc-methylene diphosphonate ( 99m Tc-MDP) described by Brenner et al (26) For 18 F À PET studies, an equivalent measurement of bone uptake is provided by standardized uptake values (SUVs), which normalize the concentration in the bone region of interest for injected activity and body weight (SUV ¼ mean kBq/ mL x body weight [kg]/injected activity [MBq]). (27) The only previous studies that used 18 F À PET to examine the regional effects of an osteoporosis treatment were a report by Frost et al (21) on the effect of risedronate on bone turnover at the lumbar spine and a study by Uchida et al (27) on the effects of alendronate on bone metabolism at the spine and femoral neck in glucocorticoid-induced osteoporosis. To date, no studies of an anabolic agent have been reported.…”

Long-Term Precision of 18F-Fluoride PET Skeletal Kinetic Studies in the Assessment of Bone Metabolism

“…The functional imaging technique of 18 F-fluoride PET allows a direct quantitative assessment of bone metabolism at specific sites of the skeleton (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12). In the early 1990s, when 18 F-FDG PET was evolving as a major tool in the field of oncology, 18 F-fluoride PET was introduced as a technique for quantifying bone metabolism by Hawkins et al, who first described the 3-compartmental kinetic model that can be applied in clinical studies (7).…”

18F-fluoride PET as a noninvasive imaging biomarker for determining treatment efficacy of bone active agents at the hip: A prospective, randomized, controlled clinical study

“…(18)(19)(20)(21) The most important role of 18 F-PET is likely to be in clinical drug development, and a number of studies have demonstrated that it is possible to quantify the direct effects of long-term pharmacological treatments for osteoporosis and other metabolic bone diseases on bone formation rate at the spine and hip. (15,(22)(23)(24) The primary objective of this study was to determine if 18 F-PET can be used as an early noninvasive biomarker of treatment efficacy at the hip by examining changes in regional bone formation rate at the proximal femur in a prospective, randomized, and controlled study of postmenopausal women with osteopenia treated with the anabolic agent teriparatide for 12 weeks.…”